Methodologic issues in acute migraine clinical trials

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Migraine is a common chronic condition with an ever-expanding therapeutic armamentarium. As new migraine therapies are investigated, the methodology of clinical trials has become increasingly important. Clinical trials should provide clinicians and patients with the information they need to assess the efficacy, safety, and comparative benefits of current and emerging therapies. The study design (e.g., crossover, parallel group) and methods, including determination of appropriate dosing, are key. The selection of primary efficacy end points is another critical factor. There is increasing evidence that complete pain relief powerfully predicts patient satisfaction with treatment and quality of life. Secondary end points, such as relief of migraine-associated symptoms, need for use of escape medication, and quality of life measurements, should also be carefully considered.

Original languageEnglish (US)
JournalNeurology
Volume55
Issue number9 SUPPL. 2
StatePublished - 2000

Fingerprint

Migraine Disorders
Clinical Trials
Quality of Life
Therapeutics
Patient Satisfaction
Cross-Over Studies
Safety
Pain

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Methodologic issues in acute migraine clinical trials. / Lipton, Richard B.

In: Neurology, Vol. 55, No. 9 SUPPL. 2, 2000.

Research output: Contribution to journalArticle

@article{5852310bcc5e4973b8fb48de788720b6,
title = "Methodologic issues in acute migraine clinical trials",
abstract = "Migraine is a common chronic condition with an ever-expanding therapeutic armamentarium. As new migraine therapies are investigated, the methodology of clinical trials has become increasingly important. Clinical trials should provide clinicians and patients with the information they need to assess the efficacy, safety, and comparative benefits of current and emerging therapies. The study design (e.g., crossover, parallel group) and methods, including determination of appropriate dosing, are key. The selection of primary efficacy end points is another critical factor. There is increasing evidence that complete pain relief powerfully predicts patient satisfaction with treatment and quality of life. Secondary end points, such as relief of migraine-associated symptoms, need for use of escape medication, and quality of life measurements, should also be carefully considered.",
author = "Lipton, {Richard B.}",
year = "2000",
language = "English (US)",
volume = "55",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9 SUPPL. 2",

}

TY - JOUR

T1 - Methodologic issues in acute migraine clinical trials

AU - Lipton, Richard B.

PY - 2000

Y1 - 2000

N2 - Migraine is a common chronic condition with an ever-expanding therapeutic armamentarium. As new migraine therapies are investigated, the methodology of clinical trials has become increasingly important. Clinical trials should provide clinicians and patients with the information they need to assess the efficacy, safety, and comparative benefits of current and emerging therapies. The study design (e.g., crossover, parallel group) and methods, including determination of appropriate dosing, are key. The selection of primary efficacy end points is another critical factor. There is increasing evidence that complete pain relief powerfully predicts patient satisfaction with treatment and quality of life. Secondary end points, such as relief of migraine-associated symptoms, need for use of escape medication, and quality of life measurements, should also be carefully considered.

AB - Migraine is a common chronic condition with an ever-expanding therapeutic armamentarium. As new migraine therapies are investigated, the methodology of clinical trials has become increasingly important. Clinical trials should provide clinicians and patients with the information they need to assess the efficacy, safety, and comparative benefits of current and emerging therapies. The study design (e.g., crossover, parallel group) and methods, including determination of appropriate dosing, are key. The selection of primary efficacy end points is another critical factor. There is increasing evidence that complete pain relief powerfully predicts patient satisfaction with treatment and quality of life. Secondary end points, such as relief of migraine-associated symptoms, need for use of escape medication, and quality of life measurements, should also be carefully considered.

UR - http://www.scopus.com/inward/record.url?scp=0033767038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033767038&partnerID=8YFLogxK

M3 - Article

VL - 55

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9 SUPPL. 2

ER -